Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News BioDelivery Sciences International Inc. BDSI

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:BDSI)

Fundamentals Snapshot (NDAQ:BDSI)

Current News (NDAQ:BDSI)

Genenta Announces Nomination of Mark A. Sirgo as Chair

GlobeNewswire April 27, 2022

Collegium Completes the Acquisition of BDSI

GlobeNewswire March 22, 2022

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates SJI, OBNK, CTXS, BDSI

PR Newswire March 1, 2022

SHAREHOLDER ALERT: WeissLaw LLP Reminds BDSI, MIME, VRS, and EPAY Shareholders About Its Ongoing Investigations

PR Newswire February 28, 2022

BioDelivery Sciences International Announces ELYXYB(TM) is Now Available in the U.S. for the Acute Treatment of Migraine

GlobeNewswire February 24, 2022

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FLOW, BDSI, CHWA, DNAA, CCMP

PR Newswire February 22, 2022

SHAREHOLDER ALERT: WeissLaw LLP Reminds BDSI, FTSI, CCMP, and FLOW Shareholders About Its Ongoing Investigations

PR Newswire February 21, 2022

BIODELIVERY SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioDelivery Sciences International, Inc. - BDSI

PR Newswire February 16, 2022

Moore Kuehn Encourages BDSI, ZWS, EYES, and GIIX Investors to Contact Law Firm

PR Newswire February 15, 2022

Bullboard Posts (NDAQ:BDSI)

time to sell

time to get out take your profit
armordeck - February 14, 2022

ONE DRUG PILL WIPES OUT COVID 19!

India's Ivermectin Blackout - Part V: The Secret Revealed ...   Sep 27, 2021 · By September 12, 2021...
zeropointenergy - October 6, 2021

it was a buy last week

on Friday afternoon,at $4.65 per share,another turnaround situation,it should do well,so glta.
coolfooldumbguy - February 18, 2019

Worth the buy ?

I got 2 strong buying ratings this morning from my bank's analysts, but I'm still skeptical 
eliasBk - May 30, 2017

This one too...

hehe
Stocktrader4bux - November 5, 2015

RE:next week

FAIL
conspiTheory - March 30, 2015